Factors affecting hepatocyte isolation, engraftment, and replication in an in vivo model

Toshiyasu Kawahara, Christian Toso, Donna N. Douglas, Mahra Nourbakhsh, Jamie T. Lewis, David Lorne Tyrrell, Garry A. Lund, Thomas A. Churchill, Norman M. Kneteman – 27 July 2010 – Human hepatocyte transplantation is an alternative treatment for acute liver failure and liver diseases involving enzyme deficiencies. Although it has been successfully applied in selected recipients, both isolation and transplantation outcomes have the potential to be improved by better donor selection.

Analysis of liver transplant outcomes for United Network for Organ Sharing recipients 60 years old or older identifies multiple model for end‐stage liver disease–independent prognostic factors

Thomas A. Aloia, Richard Knight, A. Osama Gaber, R. Mark Ghobrial, John A. Goss – 27 July 2010 – Older recipient age is associated with worse posttransplant survival. Although the median age of liver disease patients undergoing orthotopic liver transplantation (OLT) continues to rise, prognostic factors for posttransplant survival specific to older patients have not been defined.

Portal vein thrombosis and liver transplant survival benefit

Michael J. Englesbe, Douglas E. Schaubel, Shijie Cai, Mary K. Guidinger, Robert M. Merion – 27 July 2010 – Portal vein thrombosis (PVT) complicates the liver transplant operation and potentially affects waiting list survival. The implications on calculations of survival benefit, which balance both waiting list and posttransplant survival effects of PVT, have not been determined. The objective of this study is to describe the effect of PVT on the survival benefit of liver transplantation.

Quantifying growth and transformation frequency of oncogene‐expressing mouse hepatocytes in vivo

Marxa L. Figueiredo, Kristin M. Wentworth, Eric P. Sandgren – 23 July 2010 – Gene changes can affect cancer cells in many ways, but changes that increase disease severity—by allowing cells to proliferate when they should be quiescent, by enhancing their rate of growth under growth permissive conditions, or by increasing the risk that they will accumulate additional carcinogenic alterations—must be identified so that strategies to counter their effects can be developed.

Early on‐treatment prediction of response to peginterferon alfa‐2a for HBeAg‐negative chronic hepatitis B using HBsAg and HBV DNA levels

Vincent Rijckborst, Bettina E. Hansen, Yilmaz Cakaloglu, Peter Ferenci, Fehmi Tabak, Meral Akdogan, Krzysztof Simon, Ulus S. Akarca, Robert Flisiak, Elke Verhey, Anneke J. Van Vuuren, Charles A. B. Boucher, Martijn J. ter Borg, Harry L. A. Janssen – 23 July 2010 – Peginterferon alfa‐2a results in a sustained response (SR) in a minority of patients with hepatitis B e antigen (HBeAg)–negative chronic hepatitis B (CHB).

High‐dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double‐blind, randomized, placebo‐controlled trial

Ulrich F. H. Leuschner, Birgit Lindenthal, Günter Herrmann, Joachim C. Arnold, Martin Rössle, Hans‐Jörg Cordes, Stefan Zeuzem, Jasper Hein, Thomas Berg, the NASH Study Group – 23 July 2010 – In uncontrolled clinical studies, ursodeoxycholic acid (UDCA) had a beneficial effect on nonalcoholic steatohepatitis (NASH). However, a large controlled trial using UDCA (13‐15 mg/kg/day) was unable to confirm these results. Accordingly, a randomized, placebo‐controlled study was initiated with a high dose of UDCA (23‐28 mg/kg/day).

Subscribe to